
Sign up to save your podcasts
Or
The advent of immunotherapies is transforming cancer care. While early efforts have focused on enabling T cells to attack cancers, Myeloid Therapeutics is developing next-generation immunotherapies that use mRNA to train myeloid cells to attack cancer. We spoke to Daniel Getts, founder and CEO of Myeloid Therapeutics, about the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of the company’s therapeutic approach.
3.7
3939 ratings
The advent of immunotherapies is transforming cancer care. While early efforts have focused on enabling T cells to attack cancers, Myeloid Therapeutics is developing next-generation immunotherapies that use mRNA to train myeloid cells to attack cancer. We spoke to Daniel Getts, founder and CEO of Myeloid Therapeutics, about the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of the company’s therapeutic approach.
10,366 Listeners
124 Listeners
1,733 Listeners
9,232 Listeners
318 Listeners
6,741 Listeners
60 Listeners
88 Listeners
31 Listeners
146 Listeners
100 Listeners
15,294 Listeners
11 Listeners
48 Listeners
32 Listeners